The first two authors contributed equally to this study.
Letters: New Observations
Dysregulation of novel catecholamine-regulated protein 40 (CRP40) in Parkinson's disease patients
Article first published online: 20 MAR 2013
© 2013 International Parkinson and Movement Disorder Society
Volume 28, Issue 10, pages 1460–1461, September 2013
How to Cite
Lubarda, J., Groleau, S. E., Thomas, N., Ferro, M. A., Mishra, R. K. and Gabriele, J. P. (2013), Dysregulation of novel catecholamine-regulated protein 40 (CRP40) in Parkinson's disease patients. Mov. Disord., 28: 1460–1461. doi: 10.1002/mds.25402
Funding agencies: This work was funded by the Quebec Consortium for Drug Discovery and by the Canadian Institute of Health Research.
Relevant conflicts of interest/financial disclosures: Joseph P. Gabriele and Ram K. Mishra jointly hold a patent on Mortalin and its alternative gene product, CRP40.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 23 SEP 2013
- Article first published online: 20 MAR 2013
- Manuscript Accepted: 18 JAN 2013
- Manuscript Received: 11 JAN 2013